Wachtwoord vergeten?

Nog geen account op Reagila.nl?

Registreer dan nu!

Registreer

Maak hier uw Recordati in log aan. * verplicht




You are now leaving the site and will be re-directed to an external website

Accept
Melding bijwerking / Medische vraag
    • SMPC
    • Contact
    • Inschrijving nieuwsbrief
  • Log in / Registreer
    • INTERNATIONAL
    • BULGARIA
    • CZECH REPUBLIC
    • LATVIA
    • NETHERLANDS
    • RUSSIA
    • SLOVAKIA
    • UKRAINE
Reagila logo
  • Home
  • Over Reagila
    • Werkingsmechanisme

      Werkingsmechanisme

      • Werkingsmechanisme
      • Mode of action
    • Klinische data

      Klinische data

      • REAGILA in Patients with Acute Exacerbation of Schizophrenia
      • REAGILA in The Long-Term Treatment of Schizophrenia
      • REAGILA Controls Negative Symptoms in Schizophrenia
      • Controlling Everyday Functioning with REAGILA®
      • REAGILA’s Effects on Primary and Secondary Negative Symptoms: Pseudospecificity
      • The Safety and Tolerability Profile of REAGILA
      • The Management of Akathisia
      • Cariprazine and Weight Gain
  • Reagila Voorschrijven
    • Initiatie
    • Switchen
    • Doseren
    • Interacties
    • Diagnostische tools
  • Educatie & events
    • Congressen en online nascholing
    • Video’s
    • Reports
    • Reprints klinische ervaring en casuïstiek
  • Aan te vragen
    • Doseer gids
    • PSP Scheurblok
    • Boeken
    • Reprints
    • Patiëntfolder
  • PsyPraat
    • SMPC
    • Contact
    • Inschrijving nieuwsbrief
  • Log in / Registreer
    • INTERNATIONAL
    • BULGARIA
    • CZECH REPUBLIC
    • LATVIA
    • NETHERLANDS
    • RUSSIA
    • SLOVAKIA
    • UKRAINE
Skip to content

This website is only accessible for healthcare professionals. Please login below to obtain access.

Forgot password

No account yet on reagila.nl?

Register here!

Registreer

Maak hier uw Recordati in log aan. * verplicht




Algemene voorwaardenadmin2020-07-07T08:34:56+00:00
Recordati logo

This website contains information on Reagila® (cariprazine) which is based on the summary of product characteristics (smpc).
This website is intended to provide information exclusively to healthcare professionals in the european union and not intended for audience in the us or canada.
If you are not a healthcare professional, please leave the page and contact a healthcare professional.

2021/002/RecNL mei

  • Privacy Policy
  • Cookie Policy
  • Terms of Use
  • Contact us

Volg ons op

© 2020 Gedeon Richter / Recordati
facebooktwitterinstagrampinterest